510
Views
17
CrossRef citations to date
0
Altmetric
Review Article

The deubiquitinase A20 in immunopathology of autoimmune diseases

&
Pages 307-319 | Received 05 Jun 2013, Accepted 01 Mar 2014, Published online: 27 Mar 2014
 

Abstract

Deubiquitination-mediated regulation is important for homeostatic NF-κB activation. Aberrant NF-κB activation associated with various inflammatory and autoimmune disorders is linked with defects in the deubiquitinase A20. A20 is an important anti-inflammatory molecule that is induced by multiple signals and has numerous targets. Polymorphisms within the A20 locus or its altered expression are thought to contribute in development of autoimmune disorders. Further various studies in mice models underscore the biological importance of A20 in prevention of inflammatory conditions. Dysregulated A20 is also been suggested as a link between prolonged inflammation and cancer by preliminary reports. This review summarizes the existing understanding and focuses on the new developments in the field of A20 biology. These developments highlight the importance of A20 in pathophysiology of autoimmune disorders and its scope as therapeutics and a biomarker.

Acknowledgements

JP is thankful to Department of Science and Technology for financial support and IM is thankful to Council of Scientific and Industrial Research (CSIR) New Delhi, India for fellowship.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.